/
/
Clinical Trial: Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed/Refractory Multiple Myeloma
Clinical Trial: Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed/Refractory Multiple Myeloma image
Clinical Trial: Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed/Refractory Multiple Myeloma
Posted May 26, 2017

A clinical trial is open so study Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. The triplet of carfilzomib, dexamethasone and daratumumab (KdD) is being compared to the doublet of carfilzomib and dexamethasone (Kd) to compare progression free survival for myeloma patients who have relapsed after 1-3 prior therapies.

This trial is expected to open soon at the Gabrail Cancer Research Center in Canton, Ohio.

To learn more, click here:

Carfilzomib/Dara/Dex Clinical Trial

To find all eligible clinical trials for your myeloma, click here: Myeloma Clinical Trials
The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811